Already an existing partner and supplier of ingredients to Medisca, striking this agreement with SUANFARMA involved reinforcing a well-established symbiotic relationship between two companies committed to world-class quality, service, and price
Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication
Avacc 3 has significant advantages over existing whooping cough vaccines
The life sciences and pharmaceutical sectors suffer from hard-to-source biological materials, which translates into high costs in research and development
By strengthening the company's fibrotic disease development pipeline, Bridge will enhance its strategic focus on the development of comprehensive treatment solutions for idiopathic pulmonary fibrosis (IPF)
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
The KRIVIDA Novus RT-PCR kit can detect the Omicron variant, its sub-lineages, and the Delta variant in 45 minutes
On track to complete the BLA submission in the first half of 2022
Subscribe To Our Newsletter & Stay Updated
